Privo Technologies, a US-based late-stage clinical biopharmaceutical company, on Monday reported results from the CLN-004 Phase 2/3 (Cohort 1) trial evaluating PRV111, a nanoengineered, cisplatin-releasing patch intended for the treatment of non-invasive oral cancer and high-grade dysplasia (HGD).
In this trial, PRV111 delivered a 92% pathologic complete response (CR) rate, eliminated the requirement for surgery in all patients, and demonstrated durable local control.
The CLN-004 study builds on Privo's earlier clinical experience with PRV111 (CLN-001), which showed promising local tumour responses with no systemic toxicity in a first-in-human setting.
Next, Privo is initiating a registrational study of PRV111 in non-invasive oral cancer and HGD. The company will also explore PRV111 in other early malignant and premalignant lesions where non-surgical alternatives could provide significant benefits.
BodyLogicMD supports recommendation to remove black box warnings on certain forms of oestrogen
EirGenix signs second global exclusive licensing deal with Sandoz
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
enGene reports 62% six-month complete response rate for detalimogene in LEGEND trial
QIAGEN launches QIAsymphony Connect and showcases new precision oncology advances at AMP 2025
Innate Pharma cleared by FDA to launch TELLOMAK 3 Phase 3 trial of lacutamab in CTCL